Zoledronic acid improves outcomes for osteoporotic hip fractures, finds Study

• A total of 652 patients were given zoledronic acid and matched with 1926 people who got no antiosteoporosis medication. The patients who received zoledronic acid had a considerably reduced all-cause death rate than the ones who received no treatment.
• Subgroup analysis revealed that women in the zoledronic acid group had much lower mortality than males in the untreated group, despite the difference between the two groups being not significant.
• Furthermore, patients under the age of 90 who got zoledronic acid had considerably decreased mortality, regardless of the differences between groups above the age of 90 being not significant.
• The rates of future spinal compression fractures were reduced in the zoledronic acid group. There were no significant differences between groups in the incidence of new contralateral hip fractures or nonvertebral fractures.
• When it came to unfavorable outcomes, the rates of nonunion were comparable in the treated and untreated groups, and the zoledronic acid group did not see any incidences of atypical femoral fractures or osteonecrosis of the jaw.

Overall, the outcomes of this study support that zoledronic acid given inpatient is advantageous for osteoporotic hip fractures.

Reference:

Fan, W., Sun, X., Leder, B. Z., Lee, H., Ly, T. V., Pu, C. T., Franco-Garcia, E., & Bolster, M. B. (2024). Zoledronic acid for hip fracture during initial hospitalization. In Journal of Bone and Mineral Research. Oxford University Press (OUP). https://doi.org/10.1093/jbmr/zjae101